Niagen Bioscience

Niagen Bioscience

Niagen Bioscience was formed through the 2025 merger of ChromaDex and a clinical-stage subsidiary, taking the name of its flagship ingredient. The company manufactures and sells nicotinamide riboside (NR), a form of vitamin B3, under the brand name Niagen. Its core scientific premise is that NR can elevate NAD+ levels, a coenzyme linked to cellular energy and repair processes that decline with age. Robert Fried has led the entity since its ChromaDex days, steering it from an ingredients supplier into a consumer-facing business. The company's strategy centers on vertical integration of a single molecule — from patent-protected manufacturing to clinical research and direct-to-consumer sales. Its asset-class mix is narrow and product-driven: branded consumer supplements, bulk ingredient sales to other supplement formulators, and a pipeline of pharmaceutical applications. Consumer distribution runs through Amazon, its own website, and select retail partnerships. Clinically, Niagen has been studied in trials for cognitive function, muscle recovery, and metabolic conditions. Published studies have explored NR's effects on blood pressure and fatty liver (per Nature Communications, 2018), though the FDA has not approved it for treating any disease. The geographic footprint spans North America, with select distribution agreements in Europe and Asia. As a public company, Niagen Bioscience reports its finances: trailing-twelve-month revenue reached roughly $99 million with net income of $6.5 million through late 2025. The company employed approximately 100 people at year-end 2024. Unlike a venture-backed startup, it maintains no disclosed portfolio of external investments. Its structural setup includes a single manufacturing relationship with W.R. Grace for ingredient production, creating concentration risk. A notable recent development: in April 2025, the company officially changed its corporate name and stock ticker from ChromaDex to Niagen Bioscience, signaling a permanent, brand-level commitment to the NR molecule. Niagen Bioscience operates as a pure-play, single-molecule public biotech — a structure that concentrates scientific and commercial risk in one compound. Unlike diversified supplement conglomerates, its enterprise value rises and falls on regulatory outcomes and clinical trial results for nicotinamide riboside alone. The patent estate provides a defensive moat, but the company has already fought one high-profile legal battle to protect its IP, losing a 2021 appeal against a competitor. This architecture makes it unusually exposed to both regulatory shifts at the FDA and the publication of any large-scale negative trial data.